In 2003, Compugen co-founder Simchon Faigler purchased the rights to the company's Bioccelerator line of FPGA-based bioinformatics systems, creating a new firm called Biocceleration dedicated to selling and servicing the accelerated informatics system.

Two and a half years later, Biocceleration is now shifting its focus from the flagship hardware platform that has been on the market for more than a decade toward a software product that Faigler claims can offer comparable speedup to the FPGA boxes, but at a much lower cost.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.